{
    "clinical_study": {
        "@rank": "35024", 
        "arm_group": [
            {
                "arm_group_label": "dihydroartemisinin-piperaquine only", 
                "arm_group_type": "Active Comparator", 
                "description": "dihydroartemisinin -piperaquine (DP) only"
            }, 
            {
                "arm_group_label": "DP and 0.125 mg/kg primaquine", 
                "arm_group_type": "Experimental", 
                "description": "DP and single dose oral 0.125 mg/kg primaquine"
            }, 
            {
                "arm_group_label": "DP and 0.5 mg/kg primaquine", 
                "arm_group_type": "Experimental", 
                "description": "DP and single dose oral 0.5 mg/kg primaquine"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of low\n      single-dose primaquine for gametocidal activity against P.falciparum among adult\n      glucose-6-phosphate dehydrogenase (G6PD)-normal malaria patients."
        }, 
        "brief_title": "Phase2a Primaquine Dose Escalation Study", 
        "condition": "Malaria", 
        "condition_browse": {
            "mesh_term": "Malaria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male\n\n          -  Age >= 18 years and < 50 years\n\n          -  Malaria blood thick film positive\n\n          -  Presence of gametocytes on thick blood film\n\n          -  Agrees to admission to study ward for 26 hours post diagnosis and available for\n             follow up visits\n\n          -  No allergies to study drugs\n\n          -  Hemoglobin >= 8 g/dl\n\n          -  No evidence of severe or chronic disease\n\n          -  Written, informed consent"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01743820", 
            "org_study_id": "MEG001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "dihydroartemisinin-piperaquine only", 
                    "DP and 0.125 mg/kg primaquine", 
                    "DP and 0.5 mg/kg primaquine"
                ], 
                "intervention_name": "dihydroartemisinin-piperaquine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "DP and 0.125 mg/kg primaquine", 
                "intervention_name": "0.125 mg/kg Primaquine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "DP and 0.5 mg/kg primaquine", 
                "intervention_name": "0.5 mg/kg Primaquine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Primaquine", 
                "Dihydroquinghaosu", 
                "Artemisinins", 
                "Piperaquine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 8, 2013", 
        "location": [
            {
                "contact": {
                    "email": "adicko@icermali.org", 
                    "last_name": "Alassane Dicko, MD", 
                    "phone": "+223-6674-2296"
                }, 
                "facility": {
                    "address": {
                        "city": "Bamako", 
                        "country": "Mali"
                    }, 
                    "name": "Malaria Research and Training Centre"
                }, 
                "investigator": {
                    "last_name": "Alassane Dicko, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "francois@tropmedres.ac", 
                    "last_name": "Francois Nosten, MD", 
                    "phone": "+66 (0) 55 545 021"
                }, 
                "facility": {
                    "address": {
                        "city": "Mae Sot", 
                        "country": "Thailand", 
                        "zip": "63110"
                    }, 
                    "name": "Shoklo Malaria Research Unit"
                }, 
                "investigator": {
                    "last_name": "Francois Nosten, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Mali", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia", 
        "overall_contact": {
            "email": "goslingr@globalhealth.ucsf.edu", 
            "last_name": "Roland Gosling, MD, PhD", 
            "phone": "415 597 8114"
        }, 
        "overall_official": [
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Roland Gosling, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Malaria Research and Training Centre", 
                "last_name": "Alassane Dicko, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Shoklo Malaria Research Unit", 
                "last_name": "Fran\u00e7ois Nosten, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "Mali: comit\u00e9s d'\u00e9thique", 
                "Thailand: Ethical Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Baseline, Days 1, 2, 7", 
            "measure": "mosquito infectivity assessed through membrane feeding", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "reference": [
            {
                "PMID": "21951597", 
                "citation": "Gosling RD, Okell L, Mosha J, Chandramohan D. The role of antimalarial treatment in the elimination of malaria. Clin Microbiol Infect. 2011 Nov;17(11):1617-23. doi: 10.1111/j.1469-0691.2011.03660.x. Epub 2011 Sep 26. Review."
            }, 
            {
                "PMID": "17254503", 
                "citation": "Baird JK, Schwartz E, Hoffman SL. Prevention and treatment of vivax malaria. Curr Infect Dis Rep. 2007 Jan;9(1):39-46."
            }, 
            {
                "PMID": "18074034", 
                "citation": "El-Sayed B, El-Zaki SE, Babiker H, Gadalla N, Ageep T, Mansour F, Baraka O, Milligan P, Babiker A. A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS ONE. 2007 Dec 12;2(12):e1311."
            }, 
            {
                "PMID": "20194698", 
                "citation": "Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother. 2010 May;54(5):1762-8. doi: 10.1128/AAC.01135-09. Epub 2010 Mar 1."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743820"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Baseline, Hours 2, 6, 12, 24, Days 2, 3, 7, 14, 28", 
                "measure": "gametocyte prevalence and density", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Hours 1, 2, 3, 4, 6, 8, 12, 24", 
                "measure": "primaquine pharmacokinetics - area under the curve (AUC) of parent drug and metabolite", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Baseline, Hours 2, 6, 12, 24, Days 2, 3, 7, 14, 28", 
                "measure": "asexual parasite prevalence and density", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "description": "Baseline, Days 1, 2, 3, 7, 14, 28", 
                "measure": "safety measurements including hemoglobin and signs of hemolysis", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }
        ], 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Malaria Research and Training Centre, Bamako, Mali", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shoklo Malaria Research, Tak, Thailand", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Mahidol Oxford Tropical Medicine Research Unit", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Bill and Melinda Gates Foundation", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Wellcome Trust", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}